Naurex is a biopharmaceutical company focused on the discovery, development, and commercialization of novel, proprietary therapies for challenging diseases of the brain and nervous system.

All of our programs, including two rapid-acting antidepressants (rapastinel and NRX-1074) currently in clinical development, stem from our proprietary platform for discovering novel compounds that work through a new mechanism, modulation of the NMDA receptor to enhance pathways involved with synaptic plasticity.

Learn more about Naurex »

Copyright © 2015. Naurex Inc. All rights reserved.